• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2009 年甲型 H1N1 流感病毒在非洲的疫苗接种——成功与挑战。

2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.

机构信息

World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo.

出版信息

J Infect Dis. 2012 Dec 15;206 Suppl 1:S22-8. doi: 10.1093/infdis/jis535.

DOI:10.1093/infdis/jis535
PMID:23169967
Abstract

To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.

摘要

为向资源有限、原本很难获得 A(H1N1)pdm09 疫苗的国家提供针对 2009 年大流行性流感 A 型病毒 H1N1 亚型(A[H1N1]pdm09)的疫苗接种,世界卫生组织(世卫组织)协调向全世界包括非洲在内的选定国家捐赠疫苗。2010 年 2 月至 11 月期间,向 34 个非洲国家运送了 3220 万剂疫苗。在向世卫组织报告其接种活动的国家中,有 1920 万剂疫苗(64%)已接种。这些国家的人群覆盖率从 0.4%到 11%不等,中位数为 4%。所有国家都针对孕妇(接种疫苗总数的中位数比例[mpv],21%[范围,4%-72%])和卫生保健工作者(mpv,9%[范围,1%-73%])。19 个国家中有 14 个针对慢性病患者(mpv,26%[范围,5%-66%]),19 个国家中有 10 个针对儿童(mpv,54%[范围,17%-75%])。大部分疫苗是在该区域 A(H1N1)pdm09 传播高峰过后分发的。不良事件的频率和严重程度与其他灭活流感疫苗记录的情况一致。大流行性流感防备计划需要包括确保更迅速地确定疫苗供应以及向可能遭受未来大流行冲击的国家分发和进口疫苗的战略。

相似文献

1
2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.2009 年甲型 H1N1 流感病毒在非洲的疫苗接种——成功与挑战。
J Infect Dis. 2012 Dec 15;206 Suppl 1:S22-8. doi: 10.1093/infdis/jis535.
2
Vaccines against influenza A (H1N1) pandemic.甲型 H1N1 流感疫苗。
Arch Med Res. 2009 Nov;40(8):693-704. doi: 10.1016/j.arcmed.2009.10.008.
3
Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: a cohort study from 2009 to 2011.大流行流感 A(H1N1)pdm09 改进了后续年份的疫苗接种常规:来自 2009 年至 2011 年的队列研究。
Vaccine. 2013 Jan 30;31(6):900-5. doi: 10.1016/j.vaccine.2012.12.002. Epub 2012 Dec 16.
4
[Pandemic influenza A (H1N1)v vaccination status and factors affecting vaccination: Ankara and Diyarbakır 2009 data from Turkey].[甲型H1N1流感大流行疫苗接种状况及影响接种的因素:2009年来自土耳其安卡拉和迪亚巴克尔的数据]
Mikrobiyol Bul. 2011 Oct;45(4):684-96.
5
Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.在拉丁美洲和加勒比地区甲型H1N1流感大流行疫苗接种活动期间,据认为可归因于疫苗接种或免疫的事件。
Vaccine. 2015 Jan 1;33(1):187-92. doi: 10.1016/j.vaccine.2014.10.070. Epub 2014 Nov 6.
6
Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010.肯尼亚 2010 年医护人员接种单价流感 A(H1N1)2009 疫苗的效果和接种率。
Vaccine. 2013 Sep 23;31(41):4662-7. doi: 10.1016/j.vaccine.2013.07.005. Epub 2013 Jul 13.
7
Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign.2009-2010 年法国本土 H1N1 流感疫苗的人群和高危人群接种情况:全国疫苗接种运动的结果。
Vaccine. 2010 Nov 29;28(51):8157-61. doi: 10.1016/j.vaccine.2010.09.096. Epub 2010 Oct 27.
8
Seasonal influenza vaccination status among children with laboratory evidence of pandemic H1N1 infection.具有大流行 H1N1 感染实验室证据的儿童的季节性流感疫苗接种状况。
Pediatr Infect Dis J. 2011 Jul;30(7):562-5. doi: 10.1097/INF.0b013e31820bb482.
9
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.欧洲嗜睡症的发病率:在甲型 H1N1pdm09 流感大流行及疫苗接种运动之前、期间和之后。
Vaccine. 2013 Feb 6;31(8):1246-54. doi: 10.1016/j.vaccine.2012.12.015. Epub 2012 Dec 16.
10
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination.中欧疫苗咨询小组(CEVAG)关于 2009 年甲型 H1N1 流感大流行疫苗接种建议的指导意见。
Vaccine. 2010 May 14;28(22):3758-66. doi: 10.1016/j.vaccine.2010.03.072. Epub 2010 Apr 7.

引用本文的文献

1
Proposing a New Conceptual Syndemic Framework for COVID-19 Vaccine Hesitancy: A Narrative Review.提出一个新的概念性综合征框架来解释 COVID-19 疫苗犹豫:一个叙事性综述。
Int J Environ Res Public Health. 2023 Jan 14;20(2):1561. doi: 10.3390/ijerph20021561.
2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)在非洲:当前的考虑因素和未来的预测。
Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S136-S140. doi: 10.1093/cid/ciac401.
3
Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.
感染后中枢神经系统(CNS)和周围神经系统(PNS)自身免疫:非洲视角。
Front Immunol. 2022 Mar 9;13:833548. doi: 10.3389/fimmu.2022.833548. eCollection 2022.
4
The long road of pandemic vaccine development to rollout: A systematic review on the lessons learnt from the 2009 H1N1 influenza pandemic.大流行疫苗研发到推出的漫漫长路:从 2009 年 H1N1 流感大流行中吸取的经验教训的系统评价。
Am J Infect Control. 2022 Jul;50(7):735-742. doi: 10.1016/j.ajic.2022.01.026. Epub 2022 Feb 4.
5
Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.全球获取 COVID-19 疫苗:可能影响中低收入国家公平获取疫苗的因素的范围综述。
BMJ Open. 2021 Sep 30;11(9):e049505. doi: 10.1136/bmjopen-2021-049505.
6
Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response.扩大全球和国家流感疫苗体系以应对 COVID-19 大流行。
Vaccine. 2020 Nov 25;38(50):7880-7882. doi: 10.1016/j.vaccine.2020.10.055. Epub 2020 Oct 21.
7
Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic.季节性流感项目是否有助于大流行准备?对 2009 年大流行期间疫苗部署的分析。
Vaccine. 2020 Jan 29;38(5):1152-1159. doi: 10.1016/j.vaccine.2019.11.025. Epub 2019 Dec 12.
8
Factors and considerations for establishing and improving seasonal influenza vaccination of health workers: Report from a WHO meeting, January 16-17, Berlin, Germany.建立和完善卫生工作者季节性流感疫苗接种的因素和考虑:世卫组织会议报告,1 月 16-17 日,德国柏林。
Vaccine. 2019 Oct 8;37(43):6255-6261. doi: 10.1016/j.vaccine.2019.07.079. Epub 2019 Sep 6.
9
The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships.流感疫苗引入伙伴关系(PIVI):通过公私伙伴关系支持低收入和中等收入国家的流感疫苗规划发展。
Vaccine. 2019 Aug 14;37(35):5089-5095. doi: 10.1016/j.vaccine.2019.06.049. Epub 2019 Jul 6.
10
Assessing global preparedness for the next pandemic: development and application of an Epidemic Preparedness Index.评估全球对下一次大流行的防范能力:疫情防范指数的制定与应用。
BMJ Glob Health. 2019 Jan 29;4(1):e001157. doi: 10.1136/bmjgh-2018-001157. eCollection 2019.